LIVE

Home
Politics
Business
Opinion
Technology
Lifestyle
Entertainment
Video

Trending Now

Bessent Says "Formal Process" To Find Successor To Jerome Powell Has Begun

Ron Paul: Mistrusting Government About Epstein And More...

Jamie Dimon Says Private Credit Is Dangerous But Allocates $50 Billion

Yes, There Could Be A Developed Market Bond Crisis

Futures Rise, Nvidia Spikes After Trump Greenlights Selling Some Chips To China

JPMorgan Beats Top And Bottom Line On Solid Investment Banking, Trading Results

Goldman Macro Trader 'Fears Inflation Complacency' Ahead Of CPI

MP Materials Surges 10%, Apple To Announce $500 Million Partnership, Joining Pentagon As Investors

China Q2 GDP Drops To 5.2% But Beats Expectations Thanks To Subsidies And Tariff Frontrunning

China's 373MPH Maglev Train Debuts, Slashing Travel Time Between Cities

Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDA

Business December 07, 2019

This article is being updated.

Previous article: Detroit's Big Three are looking to a battery-powered future, but forging their own paths Prev Next article: Citigroup is raising its stock forecast for 2020 despite election year uncertainty Next

via CNBC December 7th 2019

MixedTimes.com
Business
Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDA

© 2015-2025 MixedTimes All Rights Reserved.

Home
Politics
Business
Opinion
Technology
Lifestyle
Entertainment
Video